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Running title – LDL and AcLDL uptake in canine hepatocytes and MSCs 
Abstract 
Low-density lipoprotein (LDL) uptake is one of a number of tests used to demonstrate hepatocyte-
like function after stem cell differentiation. Use of two compounds; LDL and acetylated LDL has been 
described despite each having different mechanisms of uptake.  Three primary hepatocyte cultures 
and three sets of mesenchymal stromal cell (MSCs) cultures, derived from both adipose tissue and 
bone marrow, were harvested from dogs. Those cells were compared to commercially available 
human and mouse bone marrow derived MSCs.  LDL receptor expression was demonstrated by gene 
expression and immunofluorescence in all primary hepatocyte cultures, undifferentiated canine 
bone marrow mesenchymal stromal cells (MSCs) and canine adipose MSCs.  Undifferentiated human 
and mouse bone marrow MSCs also expressed the LDL receptor.  In vitro, canine hepatocytes took 
up labelled LDL but not acetylated LDL.  All undifferentiated MSCs took up LDL but not acetylated 
LDL.  In conclusion, LDL and not acetylated LDL is a test of canine hepatocyte-like phenotype but this 
is not tissue or species specific and therefore is not informative assay when testing proof of MSC to 
hepatocyte differentiation. 
Key Words: hepatic, canine, MSC, mesenchymal stromal cells 
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AcLDL – Acetylated Low density lipoprotein 
Ad-MSC – Adipose mesenchymal stromal cells 
BM-MSC – Bone marrow mesenchymal stromal cells 
DMEM – Dulbecco’s modified Eagle’s media 
EBSS – Earle’s balanced salt solution 
EGTA - Ethylene glycol tetraacetic acid 
FBS – Foetal bovine serum 
LDL – Low density lipoprotein 
MSCs – Mesenchymal stromal cells 
PBS – phosphate buffered saline 
WME – William’s Media E 
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Introduction 
There has been much interest in production of hepatocyte-like cells from stem cell sources [1]. In 
human medicine the resultant cells would be anticipated to have a variety of uses such as: 
transplantation, in bio-artificial liver devices to support patients until a transplant was available, or 
allow sufficient regeneration in cases of acute hepatic failure; as an in vitro model of liver disease; or 
as an in vitro system for modelling hepatic metabolism of candidate drugs [2]. In veterinary 
medicine, although all these potential uses are present, for many the expense and logistics may be 
prohibitive.  
The pathophysiology of many spontaneous canine diseases has been shown to be similar to human 
clinical conditions for example, specifically in hepatology: hepatic encephalopathy [3] and fibrotic 
liver disease [4,5].  The ability to culture autologous stem cells, differentiate and re-implant into a 
large animal model with a comparable spontaneous disease niche to human cases is highly 
attractive. As a result, dogs are now recognised as a useful large animal translational model in the 
step between laboratory disease models and human clinical cases [6].  Use of animals with 
spontaneous disease also allows a reduction in experimental animal use.   
An additional area that would be immediately attractive is in vitro drug modelling to reduce the cost 
of development, animal experimentation and failure at phase III clinical trials [7-9].  The ability to 
produce in vitro canine hepatocytes with species specific CYP profiles would allow rapid screening of 
candidate drugs for potential hepatotoxicity not only of the parent drug but also the hepatic 
metabolic products.  This would greatly reduce the cost of drug development for the veterinary 
market but also contribute to reducing the number of animals required in pre-clinical testing. 
Furthermore, the ability to screen different breed phenotypes in vitro would hopefully avoid 
idiosyncratic breed reactions once the drug has been licensed, reducing the number of drugs 
withdrawn from the market and also reducing canine patients harmed.  
 
Isolation and culture of primary hepatocytes was first described over 40 years ago, although culture 
conditions which allow mature hepatocyte division in vitro have not been achieved, and hepatocytes 
in culture do not multiply to any appreciable extent [10]. Furthermore, the majority of functions that 
would be desired of a hepatocyte e.g. protein production, CYP activity are lost rapidly in vitro [11]. A 
final problem with primary hepatocyte cultures is batch variability; depending on donor source and 
time between death and processing [12].  As a result, the continual sacrifice of animals to supply in 
vitro hepatocytes is not ideal, especially at a time when much effort is being directed towards the 
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mantra of the 3 R’s (replace, reduce, refine) in animal research. Stem cells can be isolated without 
the need for animal sacrifice and have a high proliferative capacity.  There has been much interest in 
differentiation of stem cells towards a hepatocyte phenotype [1]. This would allow stem cells to be 
isolated from a phenotypically diverse canine population and be differentiated towards hepatocytes 
as required.  
Of the potential stem cell sources of hepatocyte-like cells, mesenchymal stromal cells (MSCs) hold 
the most immediate promise in veterinary medicine.  As MSCs can be isolated from almost any 
tissue, differences in resultant functionality from different tissue sources can be assessed [13].  Most 
commonly adipose and bone marrow are used as sources and can be expanded to large numbers 
[14,15].  
In producing hepatocyte-like cells, there is the question of how to characterise the resultant cells.  
Hepatocyte functionality is complex and as a result, a wide range of tests have been described 
including qualitative assays such as morphology and gene expression as well as functional assays 
including albumin production, urea synthesis and low-density lipoprotein (LDL) uptake [16].   One 
difficulty is that no one test is considered specific for hepatocytes, for example, although albumin is 
often used, gene expression has been demonstrated in pancreas, kidney, bone and microglial cells, 
synthesis in  bone and microglia and human BM-MSC and human Ad-MSC [17-21]. A minimum panel 
required for differentiated cells to be classified as a hepatocyte has been defined by Hengstler et al 
[22]. As it is technically demanding to provide a complete panel of testing,  demonstrating one each 
of storage, metabolic and synthetic function is commonly accepted as proof of hepatocyte-like 
phenotype [23].   
 
One of these functional assays is low density lipoprotein uptake. LDL is a transport molecule for 
lipids, including cholesterol and triglycerides, in extracellular fluid.  Specific LDL receptors on the cell 
membrane bind LDL and allow endocytosis.  In vivo, most LDL receptors are present on hepatocytes 
to supply cholesterol for bile secretion, conversion to bile acids and production of de novo 
lipoproteins [24]. Commercially, two types of fluorescently tagged LDL are available, native LDL and 
acetylated LDL (AcLDL), which is a synthetic analogue of naturally occurring oxidised LDL. Acetylated 
LDL (and oxidised LDL) is not recognised by the LDL receptor but is taken up by scavenging receptors, 
present chiefly on macrophages and endothelial cells [25]. In  vivo, oxidised LDL is responsible for 
endothelial dysfunction leading to atherosclerosis  [26]. Nahhmias et al. showed that human and rat 
primary hepatocytes took up LDL but not AcLDL [27]. Harada-Shiba, et al. [28] demonstrated that 
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culture of wild-type mouse primary hepatocytes avidly took up fluorescently labelled LDL however 
hepatocytes from LDL receptor knock-out mice failed to do so.  In stem cell differentiation to 
hepatocyte-like cells, LDL uptake is commonly used as part of confirmatory testing, yet despite this 
apparent clear-cut division, there appears to be confusion.  There is variation in whether LDL or 
AcLDL is used, with many papers describing LDL use in the abstract yet stating use of AcLDL in the 
materials section[29-32].   
 
The aims of this paper were to define if low density lipoprotein receptors were present on canine 
hepatocytes in culture by gene expression and immunofluorescence as well as comparing uptake of 
LDL and acetylated LDL by these canine hepatocytes to define which should be used to demonstrate 
a hepatocyte-like phenotype when differentiating canine stem cells.   Gene expression of the LDL 
receptor was compared between canine hepatocytes and canine bone marrow and adipose-derived 
MSC’s.  Finally LDL receptor expression by immunofluorescence as well as LDL and AcLDL uptake of 
undifferentiated canine, murine and human BM-MSC and canine Ad-MSC’s was examined. Canine 
hepatocytes were found to take up LDL and not acetylated LDL.  Undifferentiated canine, human and 
murine MSC’s also demonstrated specific LDL uptake and the presence of LDL receptors by gene 
expression and immunofluorescence.  
Methods 
The methods used in this study were approved by the R(D)SVS Veterinary Ethical Review Committee 
(Study 70:13).  
Primary cell isolation and culture  
Isolation of Canine hepatocytes 
Hepatocytes were derived from liver tissue obtained post-mortem from dogs euthanased for 
reasons unrelated to this study.  Liver tissue was acquired within 20 minutes of euthanasia.  A wedge 
of hepatic tissue with one cut surface and intact Glisson’s capsule was sectioned (between 20-100g), 
placed in William’s Media E with 10% foetal bovine serum (FBS) and 100 U/mL penicillin G and 100 
μg/mL streptomycin (WME, Invitrogen, UK) and transported to the laboratory on ice.   The digestion 
protocol was based on the methods described by Seglen [33]. The tissue was rinsed with Earl’s 
balanced salt solution (EBSS, Invitrogen, UK), placed in a Petri dish and 20-22g plastic catheters 
(Vygon, UK) inserted into the vessels on the cut surface.  Chelating buffer (490ml EBSS, 10ml of 
pH7.4 25mM EGTA  (Sigma)) at 37oC was perfused at approximately 6mls/minute was using a 20ml 
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syringe (BD, UK) for 15 minutes.  EBSS was then perfused at the same rate for 10 minutes. Finally 
collagenase buffer (50mg collagenase type II (Sigma), 200µl 1MCaCl2, 100ml EBSS) was perfused for 
between 30-45 minutes until the tissue appeared spongy and digested.    The liver capsule was then 
torn and the tissue gently agitated to release dissociated hepatocytes. The cell suspension was 
filtered through a 70µ cell strainer (BD, UK).  The remaining liver tissue was rinsed with William’s 
media E (WME) and this suspension also filtered.  The resultant suspension was centrifuged at 
350rpm for 3 minutes to pellet mature hepatocytes.  The supernatant was removed, the pellet re-
suspended and centrifugation repeated.   
Hepatocytes were plated at a density of 1 x105/cm2 in WME on collagen-coated wells.  After 3 hours 
to allow attachment, the wells were gently rinsed with PBS at 37oC before Hepatocyte culture 
medium (Lonza, UK) was added. Hepatocytes were cultured for 24 hours before further experiments 
were performed.  
 
Canine mesenchymal stromal cell isolation 
For cells derived from bone marrow, the distal femoral epiphysis from dogs was removed post-
mortem. A Jamshidi bone marrow biopsy needle (Baxter) was inserted into the medullary cavity via 
the trochanteric fossa and approximately 40mls of Dulbecco’s modified Eagle’s medium low glucose 
containing Glutamax-I (DMEM), with 10% FBS and 100 U/mL penicillin G and 100 μg/mL 
streptomycin (all Invitrogen, UK) (MSC media) injected with the resultant cell suspension collected 
from the distal segment. This was transported on ice to the laboratory. 
The cell suspension was diluted 1:1 with phosphate buffered saline (PBS) and 20mls layered onto 
15mls Ficoll Paque Premium (GE Life Sciences) in a 50ml Falcon tube.  This was then centrifuged at 
450g for 30 minutes without brake.  The cell-containing interface was removed to a fresh Falcon 
tube, PBS added and pelleted at 150g for 5 minutes. The cells were then re-suspended in 30mls of 
MSC media, transferred to a T150 and incubated at 37oC and 5% CO2. After 48 hours, media was 
removed, the flask washed with warmed PBS and fresh media added.  Media was changed every 2-3 
days and cells passaged once confluent.  
For cells derived from adipose tissue, approximately 10g of falciform fat was excised from dogs post-
mortem and placed in chilled MSC media.  After transport to the laboratory, this was finely chopped 
into 2-4mm pieces, placed in a 50ml Falcon tube and warmed PBS containing 100 U/mL penicillin G, 
100 μg/mL streptomycin and 1mg/ml collagenase Type II (Sigma-Aldrich).  This was then incubated 
with constant shaking at 37oC for 2 hours.  10% FBS was then added to inactivate the enzymes and 
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the tube centrifuged at 300g for 5 minutes.  The cell pellet was re-suspended in MSC media and 
filtered with 70µm cell strainer (BD Biosciences).   The cells were then re-pelleted, suspended in 
30ml MSC media transferred to a T150 and incubated at 37oC and 5% CO2. After 48 hours, media was 
removed, the flask washed with warmed PBS and fresh media added.  Media was changed every 2-3 
days and cells passaged once confluent.  
 
Human and Murine mesenchymal stromal cell culture 
Mouse and human bone marrow mesenchymal stem cells were purchased from Life technologies 
(Gibco Cat. No. S1502-100 and A15652 respectively).  These were thawed and processed according 
to the suppliers instructions.  10ml of warm DMEM/F12 medium containing 10% FBS and 100 U/mL 
penicillin G and 100 μg/mL streptomycin (all Invitrogen, UK) was added to the mouse cells and 10mls 
of MesenPRO RS™ added to the human cells.  Media was changed every 3 days and cells passaged 
when 80% confluent. 
Canine MSC characterisation 
Flow cytometry analysis 
Cells were suspended in FACS buffer (PBS with 1% bovine serum albumin) at a concentration of  1 
x107 cells/ml and 100µl added to 5ml Falcon tubes (BD Biosciences).  Primary antibodies and, where 
required, secondary antibodies are listed in Table 1. For CD11b staining 20µl blocking reagent: 2.4G2 
(anti-Fc receptor [BD Pharmingen]) was added for 10 minutes at room temperature prior to antibody 
addition. After incubation at 4oC in the dark with antibody, cells were washed in FACS buffer by 
centrifugation at 4oC, 250g, for 5 minutes three times. Samples were re-suspended in 500μl of FACS 
buffer and kept on ice in the dark for analysis. 1µl of SYTOX–Red (ThermoFisher) was added prior to 
analysis to allow gating of dead cells. Samples were run on a FACSCalibur and results acquired with 
CellQuestPro (both BD Biosciences).  Post-acquisition analysis was performed using FlowJo (Treestar, 
USA). Three adipose-derived MSC’s, three bone marrow-derived MSC’s, all at passage 4 were tested. 
No antibody and isotype controls were run for each cell type and experiment.  Canine peripheral 
blood mononuclear cells were used as positive control for MHCII, CD45 and CD19 and canine bone 
marrow-derived macrophages as a positive control for CD11b.  
 
Canine mesenchymal stromal cell trilineage differentiation 
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Induction of Osteogenesis and Adipogenesis 
Three adipose-derived MSC’s, three bone marrow-derived MSC’s, all at passage 3 were tested. Once 
60-70% confluence was achieved, commercially available media was used for adipogenesis and 
osteogenesis according to the manufacturer’s instructions (STEMPRO® Adipogenesis Differentiation 
Kit and STEMPRO® Osteogenesis Differentiation Kit, Invitrogen, respectively). Control cells were 
maintained in standard MSC media.  Media was aspirated from the wells and the cells rinsed in PBS 
before being fixed in 10% formaldehyde for 30 minutes. For lipid staining, the wells were then gently 
rinsed with distilled water then 60% isopropanol added for 5 minutes. This was then aspirated and 
the Oil Red O solution added.  The wells were then incubated for 5 minutes before the solution 
rinsed with distilled water until the rinse became clear.  For osteogenesis, media was aspirated from 
the wells and the cells rinsed with PBS.  Absolute ethanol was added to the wells for 30 minutes then 
aspirated and the wells allowed to dry. Alizarin red solution was then added for 5 minutes, removed 
and the wells carefully rinsed three times with distilled water.  Wells were examined grossly for 
staining as well as microscopically.  
 
Induction of Chondrogenesis 
Three adipose-derived MSC’s, three bone marrow-derived MSC’s, all at passage 3 were tested.  2.5 x 
105 MSC were aliquoted into 1.5ml polypropylene 1.5ml microcentrifuge tubes (Fischer Scientific, 
UK). These were then spun at 500g for 5 minutes to pellet the cells.  MSC media was then aspirated 
and either fresh MSC media or chondrogenic media added.  5 tubes of each cell and media type 
were run.  After 12 hours the cell pellet was gently detached from the bottom to become free-
floating by pipetting.  Media was then changed every 2-3 days for 21 days. RNA extraction was 
performed on 2 pellets in each experiment. The three remaining pellets were fixed in 4% 
formaldehyde and Toluidine blue staining performed. Pellets were embedded in paraffin wax blocks 
and sections cut using a microtome. Dewaxing was performed using xylene for 15 minutes, 
descending concentrations of ethanol (100, 95, 90, 70, and 0%) for 10 minutes each. The sections 
were rinsed in distilled water and submerged in 1% aqueous Toluidine blue solution (Sigma Aldrich) 
for 30 minutes at room temperature. The slides were then rinsed in 1 part distilled water and 4 parts 
1% HCl in 70% ethanol for  5 seconds.  The slides were then rinsed in distilled water, dried and 
mounted using DPX mountant (VWR, UK).  
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Analysis of Gene expression 
Two adipose-derived MSC’s, two bone marrow-derived MSC’s all passage three were tested along 
with 3 sets of freshly dissociated primary hepatocytes cultured for 24 hours. RNeasy mini kit 
(Qiagen, UK) was used according to the manufacturer’s instructions. Cell pellets were disrupted in 
350µl of lysis buffer using a Qiashredder (Qiagen, UK). DNA digestion was performed using DNase I 
(Qiagen, UK) at the recommended point in the RNA extraction protocol.  Total RNA was quantified 
and purity checked using absorbance spectrophotometry at 260 and 280nm (Nanodrop 1000, 
Thermo, UK).   
RNA was converted to cDNA using Omniscript reverse transcription kit (Qiagen, UK) according to the 
manufacturer’s instructions using random nanomers (Sigma-Aldrich, UK) and RNase inhibitor 
(Promega, UK). 1µg of RNA was added per reaction. 
Platinum Sybr Green Qpcr Kit (Invitrogen, UK) was used of all qPCR reactions. Reactions were 
performed on the Stratagene MX3000P (Agilent, UK). Relative gene expression was performed using 
cDNA, diluted 1:20 and 9.5µl of this added to each well. Each reaction was performed in triplicate 
and three no template controls were also performed for each primer using 9.5 µl of nuclease free 
water.  Primers are summarised in Table 2.  Cycling conditions were as follows: 2 minutes at 50oC, 2 
minutes at 95oC, then 40 cycles of 95oC x 15secs and 60oC x 30secs.  The final cycle was 95oC for 1 
minute then cooling to 60oC before monitoring for dissociation to 95oC.  The dissociation curve 
produced and lack of amplification of the no template controls were checked using MXPro Software 
(Agilent, UK).Data was analysed using Microsoft Office Excel 2003 program using the method 
described by Pfaffl [34] to calculate relative gene expression. 
LDL receptor immunofluorescence  
Three canine adipose-derived MSC’s, three canine bone marrow-derived MSC’s as well as human 
and mouse MSC’s were tested along with a canine transitional cell carcinoma cell line. Cells were 
cultured in four chambered slides (BD Biosciences) until they were approximately 50% confluent.  
Three sets of canine primary hepatocytes were cultured on collagen type I coated plastic at a 
seeding density of 1x105/cm2 for 48 hours prior to staining.  Media was removed, the cells washed 
with PBS and then fixed with 4% paraformaldehyde for 30 minutes.  The cells were washed with PBS 
three times, permiabilised with 100% ethanol for 5 minutes before repeating the wash step. Blocking 
buffer (PBS containing 10% goat serum (Invitrogen) and 0.1% Tween 20 (Sigma) was added for 1 
hour at room temperature.  This was then aspirated and rabbit anti-human LDL receptor antibody 
with known cross-reactivity with the dog (ABIN672111, antibodies-online) was diluted to 1:500 with 
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PBS containing 1% goat serum, 0.1% Tween added. This was then incubated at 4oC overnight and 
then washed three times in PBST. Fluorescently tagged goat anti-rabbit secondary antibody (Alexa 
Fluor 594 goat anti-rabbit IgG, Life Technologies), diluted 1:1000 in PBS containing 1% goat serum 
and 0.1% Tween was added and incubated at room temperature in the dark for 1 hour. Nuclear 
staining with DAPI was performed as described previously.  Secondary only and no antibody controls 
were also performed for each cell type.  For each sample tested, 500 cells were examined and the 
percentage positively staining was calculated.  
 
DiI-LDL and DiI-AcLDL uptake 
Sets of three canine adipose-derived MSC’s, three canine bone marrow-derived MSC’s, human and 
mouse MSC’s, three canine primary hepatocytes cultured for 48 hours were tested along with a 
canine transitional cell carcinoma cell line. DiI-LDL and acetylated DiI-LDL (both Invitrogen, UK) were 
diluted to 20µg/ml in appropriate culture media and added to cell culture wells for 3 hours.  Wells 
were then washed with PBS three times and fixed with 4% paraformaldehyde for 30 minutes.  
Nuclear staining with DAPI was performed as described previously.  The slides were then washed 
with PBST and examined using fluorescent microscopy.  No LDL controls were also performed. For 
each sample tested, 500 cells were examined and the percentage positively taking up the compound 
was calculated. 
 
Results 
Canine MSC can be derived from bone marrow and adipose tissue and demonstrate trilineage 
differentiation.  
Both canine Ad-MSC and BM-MSC had a similar level of positive staining for CD44 (23.6% and 26.0% 
respectively ( and CD90 (44.6% and 40.0% respectively) (Figure 1 and Table 3). Both cell types were 
negative for MHCII, CD11b, CD19 and CD45 by flow cytometry (Figure 1 and Table 3).  On flow 
cytometry, both Ad-MSC and BM-MSC were negative for CD105 and STRO-1, which have previously 
been reported to be expressed by canine BM-MSC using immunocytochemistry [37].  Both Ad-MSC 
and BM-MSC’s appeared strongly positive for both these markers with immunocytochemistry with a 
negative control demonstrating no staining (Supplementary information 1). 
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 Multiple Oil red-O positively-staining vacuoles were detected in the cytoplasm of both Ad-MSC and 
BM-MSC after adipocyte differentiation (Figure 2 A&B). Alizarin red staining demonstrated 
calcification osteogenic differentiation in both cell types (Figure 2 C&D).  Metachromatic staining 
suggestive of cartilage formation was shown after chondrogenic differentiation (Figure 2 E&F).   
Gene expression analysis revealed upregulation in aggregan but not Sox9 expression (Supplementary 
information 2). 
 
Canine primary hepatocytes and MSC demonstrate low density lipoprotein receptor expression by 
real-time PCR and immunofluorescence 
Gene expression relative to the three reference genes demonstrated LDL-receptor expression in 
canine BM-MSC and Ad-MSC of a similar magnitude to canine primary hepatocytes (Figure 3). Of the 
three primary hepatocyte cultures, relative expression varied from 0.03-0.3.  These were 
hepatocytes in the first 24 hours of culture   
LDL receptor expression was documented by immunofluorescence in canine hepatocytes, canine, 
murine and human BM-MSC’s as well as the canine Ad-MSC’s (Figure 4).  All cell types demonstrated 
immunofluorescence.  The three primary canine hepatocyte cultures median percentage of positive 
cells was 96.8% (range 94.8- 98.2%). Canine Ad-MSC’s median percentage positive was 98.8% (range 
98.2 – 99.2%). The canine, human and murine BM-MSC’s percentage positive cells were: 98.6% 
(range 97.8-99.9%), 99.5% (range 99.4-99.8%) and 99.6% (range 99.4-99.8%) respectively. Negative 
controls demonstrated a low level of background immunofluorescence in the canine primary 
hepatocytes and canine BM-MSC’s.  The transitional cell line demonstrated no binding.  
 
Hepatocytes and MSC’s take up LDL and not AcLDL 
After incubation with DiI-LDL, all canine hepatocytes, BM-MSC and Ad-MSC as well as murine and 
human MSC demonstrated uptake of this compound whilst the transitional cell carcinoma cells 
demonstrated no uptake (Figure 5).  After incubation with AcLDL, none of the canine, murine or 
human MSC’s were positive although some fluorescent extracellular debris was noted (Figure 6).   
Within the canine hepatocyte cultures although the vast majority of cells showed no uptake, there 
were sporadic individual cells which demonstrated avid uptake of AcLDL (Figure 6A demonstrates a 
cluster of these cells).  Overall, a median of 4.5% of the canine primary hepatocyte culture cells were 
positive for AcLDL uptake (range 3.2-6.7%).  
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Discussion 
From these results, canine primary hepatocytes in culture have LDL receptor expression as 
demonstrated by gene expression and also immunofluorescence.  Comparing uptake of LDL and   
AcLDL in the hepatocyte culture demonstrates that LDL uptake is mediated by this receptor as only 
LDL and not AcLDL is taken up by the hepatocytes.  Therefore, uptake of LDL and not AcLDL should 
be used as part of the demonstration of hepatocyte-like function for canine cells. This is consistent 
with the previously reported function of human and mouse primary hepatocytes [27,28]. It is of note 
that sporadic cells in the hepatocytes culture plates took up AcLDL avidly and it is likely that these 
are either Kuppfer cells or endothelial cells which were isolated along with hepatocytes from the 
liver digestion process. Both these cell types are reported to contain the scavenging receptors which 
endocytose acetylated or oxidised LDL [25,35]. This is consistent with the report by Babaev, et al. 
[36] who found that human primary hepatocyte cultures almost uniformly took up LDL with only 5% 
of cells in culture taking up modified LDL.  These were identified as macrophages or endothelial cells 
based on their ability to take up tagged formaldehyde-treated albumin and carboxylates 
microspheres. In the present study only 4.5% of cells in the primary hepatocyte cultures took up 
AcLDL, a similar number to the previous study. 
 
The isolated and cultured canine BM-MSC and Ad-MSC’s demonstrated adipogenic and osteogenic 
potential.  We have previously demonstrated isolation and characterisation of canine BM-MSC, 
including the demonstration of chondrogenic differentiation was based on toluidine blue staining, 
increased collagen type II gene expression and Sox9 immunostaining [37].   In the present study, 
Toludine blue metachromatic staining of cartilage pellets, although present, was less dramatic than 
that demonstrated by Requicha et al. [38].   Both cell types also demonstrated significant increases 
in aggrecan gene expression, the major proteoglycan in articular cartilage produced by chondrocytes 
[39].  Interestingly, both cell types showed no increase in Sox9 expression, which is the master-
regulator of chondrogenesis.  As one of the functions of Sox9 is to bind to the aggrecan promoter 
and upregulate aggrecan expression, this appears an unusual result [40]. One possible explanation 
for this apparent paradox is that gene expression during differentiation is dynamic and Sox9 gene 
expression is shut-off during final maturation of chondrocytes into hypertrophic chondrocytes[41]. 
Therefore it is possible up-regulation of Sox9 was missed in these samples.  Another possibility is 
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that chondrogenesis is dysregulated and stimulation of gene expression is down-stream of Sox9 
expression. From the literature there appears to be variation in Sox9 expression. Reich et al. 
detected an increase in Sox9 with BM-MSC but a decrease with Ad-MSC [42]. This corroborated with 
more convincing cartilage formation in BM-MSC by histology and up-regulation of Collagen 2A1 only 
in BM-MSC. Other authors have demonstrated convincing chondrogenic differentiation of both 
canine Ad-MSC and BM-MSC with Sox9 expression and also convincing chondrogenic differentiation 
with no Sox9 up-regulation [38,43,44].  However other studies have failed to demonstrate 
chondrogenesis in canine MSC’s [45,46].  These disparate results need to be viewed with knowledge 
that a donor age-related reduction in differentiation ability of MSCs has been demonstrated, along 
with variation in ability according to donor site and passage number [43,47-49]. 
In this study, both Ad-MSC and BM-MSc demonstrated no expression of  CD105 or STRO-1 by flow-
cytometry yet appeared positive on immunocytochemistry.  Canine BM-MSC has previously reported 
to be positive for CD105 and STRO-1 by immunocytochemistry [37], however Screven et al. found 
both canine Ad-MSC and BM-MSC to be negative on flow-cytometry but positive for CD105 gene 
expression by real-time PCR [50].  It is possible that the antibody is not suitable for flow-cytometry 
however further investigation will be required to define if CD105 expression is a useful marker for 
canine MSC’s.   
Both undifferentiated canine BM-MSC and Ad-MSC demonstrated LDL receptor gene expression of a 
comparable magnitude to canine primary hepatocytes.  Furthermore, undifferentiated canine, 
mouse and human BM-MSCs and also undifferentiated canine AD-MSCs stained for the presence of 
the LDL receptor by immunocytochemistry.  Functionality of the receptor was confirmed by LDL 
uptake and not AcLDL uptake.  Therefore it would appear that for differentiation studies producing 
hepatocyte-like cells, confirming LDL uptake is not specific for a hepatocyte phenotype and in 
addition it should not be used for MSC to hepatocyte differentiation studies. 
It has been demonstrated that mouse BM-MSC express LDL-oxidised receptors (LOX-1) and take up 
DiI-oxidised-LDL (the biological analogue to acetylated-LDL) and also express LOX-1 by gene 
expression and Western blot, which is in contrast to the present study, where all MSC’s tested 
(canine Ad-MSC and canine , murine and human BM-MSC) were found not to take up AcLDL [51,52].  
These apparent differences may be an artefact of culture conditions rather than a fundamental 
cellular difference as Liesveld et al. showed that human BM-MSC took up DiI-LDL in standard 
McCoy’s media with 10% FCS, whilst culture in McCoy’s’ with 25% serum and 1µmol/L 
hydrocortisone, this reduced, and DiI-AcLDL uptake increased [53].  Both the mouse and human BM-
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MSC’s were cultured under the conditions recommended by the supplier and produced identical 
results to the canine MSC’s i.e. no AcLDL uptake but avid LDL uptake.   
In line with the theory that MSC are fibroblast populations[54], it has been demonstrated that 
fibroblasts express the LDL receptor, take up LDL but not modified LDL[55-58]. Therefore in this 
respect, the presence of LDL receptors and specific uptake of LDL on MSC’s is not surprising.  
In summary, LDL receptor is present on canine primary hepatocytes in culture. LDL and not AcLDL 
uptake is a function of canine primary hepatocytes.  LDL receptor expression and LDL uptake is not 
specific to a hepatocyte phenotype and undifferentiated MSC’s express the LDL receptor and 
endocytose LDL.  Assessing the effect of culture conditions on LDL receptor expression and the cells 
ability to take up LDL and AcLDL would be useful to assess if canine MSC demonstrate the same 
plasticity as human BM-MSC in regard to LDL and AcLDL uptake. 
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Marker 
 
Primary antibody Dilution Isotype Flurophore /secondary 
MHCII MCA1044GA, AbD  
Serotec 
1:50 IgG2a FITC 
CD11b MCA1777S, AbD  
Serotec 
1:10 IgG1 Goat anti mouse Alexa 
Fluor 488 A-11001, Life 
technologies  
CD19 ab24936, Abcam 1:100 IgA FITC 
CD44 MCA1041GA 1:10 IgG2a Goat anti rat Alexa Fluor 
488 A-11006, Life 
Technologies  
CD45 MCA1042G, AbD  
Serotec 
1:10 IgG2 Phycoerythrin 
 
CD90 MCA1036G, AbD  
Serotec 
1:20 1Gg2b Goat anti rat Alexa Fluor 
488 A-11006, Life 
Technologies 
CD105 orb10285 Biorbyt 1:50 Polyclonal 
rabbit 
Goat anti rabbit Alexa 
Fluor 488, Life 
Technologies 
STRO1 MAB1038 R&D 
Systems 
1:100 IgM Goat anti-mouse  IgG 
A-11001 (Life 
technologies) 
 
Table 1 Cell surface markers and antibodies used for flow cytometry 
 
Table 1 Cell surface markers and antibodies used for flow cytometry 
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Gene Primer Sequences PCR Amplicon 
length  
(base pairs) 
Genebank 
Accession 
number 
Primer Sequence 
Reference 
HPRT Forward: AGCTTGCTGGTGAAAAGGAC 
Reverse:  TTATAGTCAAGGGCATATCC 
104 XM_005625362 Brinkhof et al. 
(2006) 
B2MG Forward: TCCTCATCC TCCTCGCT 
Reverse:  TTCTCTGCTGGGTGTCG 
85 XM_535458 Brinkhof et al. 
(2006) 
RPL8 Forward: CCATGAATCCTGTGGAGC 
Reverse:  GTAGAGGGTTTGCCGAT 
64 XM_532360 Brinkhof et al. 
(2006) 
LDL-
Receptor 
Forward: ATTGTGGTGGATCCCGTGC 
Reverse: GAAAGATCCAGGGTGATGCCATT 
149 XM_00632869.1 --- 
 
Table 2  Primers used in quantitative polymerase chain reaction 
 
Table 2  Primers used in quantitative polymerase chain reaction 
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Cell 
Type 
 
Marker Mean 
Percent positive 
Standard  
Deviation 
Ad-MSC CD90 43.3 2.6 
 
 CD44 
 
CD105 
 
CD45 
 
STRO-1 
 
CD11b 
 
CD19 
 
MHCII 
21.6 
 
0.34 
 
0.19 
 
0.44 
 
0.48 
 
0.51 
 
0.55 
2.2 
 
0.17 
 
0.02 
 
0.22 
 
0.22 
 
0.29 
 
0.51 
 
 
BM-MSC 
 
CD90 
 
 
39.5 
 
3.4 
 CD44 
 
CD105 
 
CD45 
 
STRO-1 
 
CD11b 
 
CD19 
 
MHCII 
27.3 
 
 0.8 
 
0.27 
 
0.64 
 
0.88 
 
0.81 
 
0.66 
3.8 
 
0.18 
 
0.13 
 
0.32 
 
0.30 
 
0.02 
 
0.37 
 
Table 3 Results of flow cytometry for cell surface markers. The mean percent positive from 3 sets of Ad-MSC and BM-MSC 
with standard deviation. Both MSC cells types were positive for CD90 and CD44 and negative for CD11b, CD19, CD45, 
MHCII, STRO-1 and CD105.  
 
Table 3 Results of flow cytometry for cell surface markers. The mean percent positive from 3 sets of Ad-MSC and BM-MSC 
with standard deviation. Both MSC cells types were positive for CD90 and CD44 and negative for CD11b, CD19, CD45, 
MHCII, STRO-1 and CD105.  
 
Figure Legends 
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Figure 1: Expression of cell surface molecules in  canine MSC’s by flow cytometry 
Showing live cell gating and representative histogram demonstrating canine adipose and bone 
marrow MSC cell surface molecule expression. The shaded area represents the negative isotype 
control and open line represent sample labelled with the indicated cell surface molecule.  
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Figure 2 Adipogenic, osteogenic and chrondrogenic differentiation of canine MSC’s 
Oil red-O after adipogenic differentiation BM-MSC (A), Ad-MSC (B). Alizarin red staining after 
osteogenic differentiation BM-MSC (C), Ad-MSC (D). Toludine blue staining after chondrogenic 
differentiation  BM-MSC (E), Ad-MSC (F). White bar represents 25µM.  
 
Figure 3: LDL-receptor gene expression in canine primary hepatocytes and Ad-MSC and BM-MSC 
Relative gene expression of LDL receptor normalised to three reference genes (B2MG, RPL8, HPRT).  
Three sets of fresh cultured canine primary hepatocytes and two each of Ad-MSC and BM-MSC 
cultures. Three replicates per cell type were performed. 
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Figure 4: LDL receptor immunofluorescence  
Canine hepatocytes (A), Canine transitional cell carcinoma (B), Ad-MSC (C), BM-MSC (D), human BM-
MSC (E) and  murine BM-MSC (F). Nuclei stained with DAPI.  White bar represents 100µm. Canine 
hepatocytes showed membrane binding and intense fluorescent intra-cytoplasmic accumulations. 
All MSC’s demonstrated strong binding of LDL receptor antibody.  Secondary antibody negative 
controls showed no fluorescence (not shown). Canine transitional cell carcinoma cells demonstrated 
no antibody binding.   
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Figure 5: DiI-LDL uptake in canine primary hepatocytes and MSC’s 
Canine hepatocytes (A), Canine transitional cell carcinoma (B), Ad-MSC (C), BM-MSC (D), human BM-
MSC (E) and  murine BM-MSC (F). Nuclei stained with DAPI.  White bar represents 100µm.  Canine 
hepatocytes and all MSC’s demonstrated strong uptake of DiI-LDL.  Canine transitional cell 
carcinoma cells showed no uptake.  
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Figure 6: DiI-AcLDL uptake in canine primary hepatocytes and MSC’s 
Canine hepatocytes (A), Canine transitional cell carcinoma (B), Ad-MSC (C), BM-MSC (D), human BM-
MSC (E) and  murine BM-MSC (F). Nuclei stained with DAPI.  White bar represents 100µm.  In the 
canine hepatocyte cultures, a few sporadic cells demonstrated avid AcLDL uptake however the vast 
majority of cells showed no uptake.  No uptake was seen in all MSC’s or transitional cell cultures with 
only some extracellular fluorescent debris seen.  
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Supplementary information 1 
 
Immunocytochemistry of canine MSC for STRO-1 and CD105 
 
Antibody information 
Marker 
 
Primary antibody Dilution Secondary 
antibody 
Dilution Flurophore  
STRO1 IgM mouse anti-
human  
MAB1038 (R&D 
Systems) 
1:100 Goat anti-mouse  
IgG 
A-11001 (Life 
technologies) 
1:500 Alexa Fluor® 
488 
 
CD105 Polyclonal rabbit 
orb10285 
(Biorbyt) 
1:50 Goat anti-rabbit 
IgG 
A-11008 (Life 
technologies) 
1:500 Alexa Fluor® 
488 
 
 
Protocol 
Canine Ad-MSC, BM-MSC and canine transitional cell carcinoma cells were used and experiments 
were performed in triplicate.  Cells were cultured in four chambered slides (BD Biosciences) until 
they were approximately 50% confluent.  Media was removed, the cells washed with PBS and then 
fixed with 4% paraformaldehyde for 30 minutes.  The cells were washed with PBS three times, 
permiabilised with 100% ethanol for 5 minutes before repeating the wash step. Blocking buffer (PBS 
containing 10% goat serum (Invitrogen) and 0.1% Tween 20 (Sigma-Aldrich, UK) was added for 1 
hour at room temperature.  This was then aspirated and the appropriate dilution of antibody in PBS 
containing 1% goat serum, 0.1% Tween added (Table 2). Slides were incubated at 4oC overnight and 
then washed three times. The secondary antibody, again diluted in PBS containing 1% goat serum 
and 0.1% Tween was added and incubated at room temperature in the dark for 1 hour.  Slides were 
then rinsed three times with PBST and 4', 6-diamidino-2-phenylindole (DAPI) at a concentration of 
200ng/ml for 30 minutes added.  The slides were then washed with PBST and examined using 
fluorescent microscopy (Zeiss, Aviovert 40) and Zeiss Aviovision 4.7 software. Secondary only and no 
antibody controls were also performed for each cell type and antibody. 
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Results 
 
Figure Legend: STRO1 and CD105 immunocytochemistry of canine MSC’s 
Representative images of canine Ad-MSC and BM-MSC demonstrating positive staining for STRO1 
and CD105.  TCC – canine transitional cell carcinoma cell line, demonstrating no staining for both 
markers.  
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Supplementary Information 2  
Chondrocyte gene expression of chondrogenic differentiation of canine MSC’s 
 
Primer sequences 
Gene Primer Sequences PCR Amplicon 
length  
(base pairs) 
Genebank 
Accession 
number 
 
HPRT Forward: AGCTTGCTGGTGAAAAGGAC 
Reverse:  TTATAGTCAAGGGCATATCC 
104 XM_005625362  
B2MG Forward: TCCTCATCC TCCTCGCT 
Reverse:  TTCTCTGCTGGGTGTCG 
85 XM_535458  
RPL8 Forward: CCATGAATCCTGTGGAGC 
Reverse:  GTAGAGGGTTTGCCGAT 
64 XM_532360  
Aggrecan 
 
Forward: ATCAACAGTGCTTACCAAGACA 
Reverse: ATAACCTCACAGCGATAGATCC 
122 XM_005618252.1  
Sox9 
 
Forward: GCTCGCAGTACGACTACACTGAC 
Reverse: GTTCATGTAGGTGAAGGTGGAG 
101 NM_001002978.1  
 
RNeasy mini kit (Qiagen, UK) was used according to the manufacturer’s instructions. Cell pellets 
were disrupted in 350µl of lysis buffer using a Qiashredder (Qiagen, UK). DNA digestion was 
performed using DNase I (Qiagen, UK) at the recommended point in the RNA extraction protocol.  
Total RNA was quantified and purity checked using absorbance spectrophotometry at 260 and 
280nm (Nanodrop 1000, Thermo, UK).   
RNA was converted to cDNA using Omniscript reverse transcription kit (Qiagen, UK) according to the 
manufacturer’s instructions using random nanomers (Sigma-Aldrich, UK) and RNase inhibitor 
(Promega, UK). 1µg of RNA was added per reaction. 
Platinum Sybr Green Qpcr Kit (Invitrogen, UK) was used of all qPCR reactions. Reactions were 
performed on the Stratagene MX3000P (Agilent, UK). Relative gene expression was performed using 
cDNA, diluted 1:20 and 9.5µl of this added to each well. Each reaction was performed in triplicate 
and three no template controls were also performed for each primer using 9.5 µl of nuclease free 
water.  Primers are summarised in Table 3.  Cycling conditions were as follows: 2 minutes at 50oC, 2 
minutes at 95oC, then 40 cycles of 95oC x 15secs and 60oC x 30secs.  The final cycle was 95oC for 1 
minute then cooling to 60oC before monitoring for dissociation to 95oC.  The dissociation curve 
produced and lack of amplification of the no template controls were checked using MXPro Software 
(Agilent, UK).Relative gene expression compared undifferentiated MSC and Chondrocyte 
differentiated MSC.  Rest 2009 gene expression software was used for analysis (http://rest-
2009.gene-quantification.info).  
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Agrecan and Sox9 were compared to the three reference genes. 
 
 
 
A – AD-MSC chondrocyte differentiation compared to undifferentied AD-MSC. 
B – BM-MSC chondrocyte differentiation compared to undifferentied BM-MSC 
AGG - Aggrecan 
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